Compare VREX & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | AQST |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.6M | 504.0M |
| IPO Year | 2016 | 2007 |
| Metric | VREX | AQST |
|---|---|---|
| Price | $11.97 | $4.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.67 | $9.00 |
| AVG Volume (30 Days) | 202.1K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $811,000,000.00 | $67,430,000.00 |
| Revenue This Year | $5.35 | $10.08 |
| Revenue Next Year | $3.88 | $49.60 |
| P/E Ratio | $232.40 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $6.76 | $2.22 |
| 52 Week High | $14.57 | $7.55 |
| Indicator | VREX | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 61.43 | 60.07 |
| Support Level | $11.43 | $3.70 |
| Resistance Level | $12.61 | $4.50 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 89.06 | 84.78 |
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.